MicroPort® EP’s RhythmWatch™
Single Lead ECG Recorder Gains CFDA (Class II) Approval

On November 15, RhythmWatch™ Single lead ECG Recorder, in-house developed by Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP"), obtained the approval from China Food and Drug Administration ("CFDA") (Class II).

RhythmWatch™ Single-lead ECG Recorder designed by MicroPort® EP is composed of mobile recorders, host software, mobile terminal software and server front-end software, which is used for medical institutions to collect, record and send ECG signals for patients. RhythmWatch™ Single-lead ECG Recorder is designed in patch style, so patients can wear it for a long time with continuous acquisition of ECG signal. The ECG signals could be replayed with the software. The device could communicate with mobile APP, showing the real-time electrocardiogram, and it can provide immediate view and auxiliary diagnosis for physicians. Through the server front-end software, it can not only make the electrocardiogram display in real time, but also realize the sharing of ECG data. The launch of this device is expected to improve the efficiency of diagnosis and treatment for outpatients, and ease the burden for patients who need follow-up after discharge as well.

RhythmWatch™ Single lead ECG Recorder is the first portable ECG monitoring product of MicroPort® EP launched in the China market. Its launch marks another step forward for MicroPort® EP in building a complete cardiac EP solution platform. Dr. Yiyong Sun, President of MicroPort® EP, said: "It is well acknowledged that smaller, wireless and smarter electrophysiological medical hardware has a promising future in the era of mobile internet. In the future, MicroPort® EP will continue to combine the professional medical service with modern IT technology to develop more innovative products to benefit more patients and doctors."
WALTZ™ Gains Regulatory Approval in Brazil

On October 30, WALTZ™ CoCr Coronary Stent System ("WALTZ™"), in-house developed by Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort™"), received approval from Brazil’s National Health Surveillance Agency (in Portuguese, Agência Nacional de Vigilância Sanitária - ANVISA). The product had received CE mark and gained regulatory approvals in Argentina, Peru, the Philippines, Indonesia, and etc.

WALTZ™ is indicated for the treatment of coronary artery stenosis or occlusion. It has L605 Cobalt-Chromium alloy stent architecture with three different stent designs. As the third-generation bare metal stent of MicroPort®, WALTZ™ has strong radial strength and excellent flexibility, crossability, trackability, and pushability to achieve the best surgical outcome.
FOXTROT™ NC PTCA Balloon Catheter Gains Regulatory Approval in Argentina

FOXTROT™ NC PTCA Balloon Catheter, in-house developed by MicroPort®, received regulatory approval from the ANMAT, Argentina’s National Administration of Drugs, Foods and Medical Devices. Previously, the product had received CE mark and gained approvals from US Food and Drug Administration, China Food and Drug Administration, Japan’s Ministry of Health, Labour and Welfare, as well as regulatory authorities in the Philippines, Thailand, Brazil, Mexico and etc.
MicroPort® Attends TCT to Display Firehawk® and Firesorb®

From October 29 to November 2, MicroPort® attended 2017 Transcatheter Cardiovascular Therapeutics ("TCT") held in Denver, US, and broadcasted a high-risk live case of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk")

On October 31, Professor Bo Xu of Fuwai Hospital of Chinese Academy of Medical Sciences released the one-year clinical and angiographic follow-up results (clinical, angiographic, IVUS, and OCT findings) of FUTURE I Trial of Firesorb® Bioresorbable Rapamycin Target Eluting Coronary Scaffold System ("Firesorb"). FUTURE-I Trial is a perspective, single arm, First-in-Man ("FIM") clinical trial of evaluating the safety and efficacy of Firesorb® in the treatment of coronary heart diseases. It enrolled 45 patients. The primary endpoint is 30-day target lesion failure ("TLF"), including cardiac death, myocardial infarction of target vessel and ischemia-driven TLR (Target lesion Revascularization). The one-year clinical results showed that the occurrence of TLF is zero, the occurrence of patient-oriented composite endpoint ("PoCE") is 2.2%, and there is no death and ARC (Academic Research Consortium) defined stent thrombosis. The one-year in-device late lumen loss is 0.13mm and no restenosis occurred. The one-year clinical, angiographic, IVUS, and OCT results once again demonstrated Firesorb®’s feasibility, safety and efficacy in the treatment of single de novo lesions. Firesorb®’s pivotal clinical study FUTURE II trial, a prospective, multi-center, randomized clinical trial, aiming to evaluate the safety and efficacy of Firesorb® in the treatment of coronary artery atherosclerosis, successfully enrolled the first patient in August.
MicroPort® Orthopedics Attends 12th COA

From November 15 to November 18, MicroPort® Orthopedics attended the 12th Chinese Orthopedic Association ("COA") and hosted series of symposiums.

During the COA, MicroPort® Orthopedics for the first time displayed the first-generation prototype of the Minimal Invasive, High Efficiency Orthopedic Robotic System, which attracted wide attention from the attendees. The project "Research on Minimal Invasive, High Efficiency Orthopedic Robotic System(117,666),(882,994)" was listed in the National Key Research & Development ("R&D") Plan, falling into the category of "Digital Diagnostic Equipment R&D." As the first domestically developed joint surgical robotic system, it drew attention from overseas experts for its unique high dexterity, light-weight manipulator design. During the COA, Professor Yibin Wei of Huashan Hospital of Fudan University, Director Weiping Ji of Lishui People's Hospital, director Chengdong Zhu of Yizheng People's Hospital, Professor Yunsu Chen of Shanghai Sixth People's Hospital introduced the advantages, steps, surgical skills of SuperPath™ Micro-posterior Total Hip Arthroplasty ("SuperPath™") and shared his clinical experience.

On November 16, MicroPort® Orthopedics hosted a symposium on total knee arthroplasty ("TKA") surgical technique and clinical experience in medial pivot knee. Professor Yihe Hu of Xiangya Hospital of Central South University was invited to share the surgical technique of using EVOLUTION™ Medial Pivot Total Knee System ("EVOLUTION™") to treat varus knee. Professor Hu first explained the standard TKA surgical technique for varus knee.

During the COA, many attendees visited MicroPort® Orthopedics booth and showed great interest in SuperPath™ technique, EVOLUTION™ knee as well as spine and trauma products. Zixin Weng, President of MicroPort® Orthopedics China, said: "MicroPort® Orthopedics will continue to launch professional academic activities and diversify innovative product lines to offer more orthopedic solutions for patients in China, Asia and the whole world."
MicroPort® Endovascular Attends CEC 2017

MicroPort® Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") recently attended the 10th China Endovascular Course & 2017 National Continuing Education Program for Vascular Surgeons ("CEC 2017") that was held in the Beijing National Convention Center, to broadcast surgeries as well as host satellite meetings and academic symposiums with experts in attendance.

During the conference, MicroPort® Endovascular demonstrated the clinical performance of its products by surgical videos. Afterwards, MicroPort® Endovascular hosted a satellite meeting, in which Professor Changwei Liu of Peking Union Medical College Hospital was invited as the chairman, and Professor Wei Ye of Peking Union Medical College Hospital, Qingsheng Lu of Shanghai Hospital, Professor Jue Yang of Zhongshan Hospital of Fudan University, and Professor Xinwu Lu of Shanghai Ninth Hospital of Shanghai Jiaotong University were invited as the guest speakers to share clinical studies and their clinical experience in Castor®, Reewarm® PTX and Minos™ with the attendees.
MicroPort® NeuroTech Attends 17th OCIN

From October 26 to October 29, MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech") attended the 17th Oriental Conference of Interventional Neuroradiology ("OCIN 2017") and displayed APOLLO Intracranial Stent System ("APOLLO"), WILLIS Intracranial Stent Graft System ("WILLIS"), and other core products.

In the OCIN, live cases are always the highlighted session. On October 30, Professor Ziliang Wang of Henan Provincial People’s Hospital used APOLLO to treat long-segment chronic total occlusion, and Professor Chuhan Jiang of Beijing Tiantan Hospital of Capital Medical University used WILLIS to treat left ophthalmic artery aneurysms. The two cases both achieved successful results and demonstrated the excellent performance of MicroPort® NeuroTech products, which attracted wide attention from experts in attendance.

In OCIN 2017, many experts visited MicroPort® NeuroTech booth and exchanged ideas with MicroPort® NeuroTech R&D staff regarding possible difficulties in clinical trials, as well as new development and new trend in the field of neurovascular intervention. The experts said they are looking forward to the market launch of Tubridge Vascular Reconstruction Device ("Tubridge"), an innovative device in-house developed by MicroPort® NeuroTech in the treatment of cerebral aneurysms, to benefit more domestic patients.
MicroPort® Orthopedics Invites Professor David Blaha for Academic Exchange

From October 31 to November 4, MicroPort® Orthopedics invited Professor David Blaha, an orthopedic surgeon at the University of Michigan Health System, to attend the Medial Pivot Knee Roadshow activities. As the inventor of Evolution®, Professor Blaha used his professional knowledge and clinical experience to help the attendees get a better understanding in the cutting-edge technologies and development trend of total knee replacement through lectures and expert consultation.

Professor Blaha has been engaged in studying knee biomechanics for 40 years with rich experience in biomechanics of orthopedic implant and prosthesis design. In 1980s, he started to design prosthesis that can restore the movement of a natural knee. In early 1990s, his determination led to the first prototype of the medial pivot knee. In 1998, after the approval of US Food and Drug Administration, the first-generation ADVANCE® Total Knee Replacement System was launched in the US. Based on the success of ADVANCE® knee, Professor Blaha designed the second-generation EVOLUTION™ Medial Pivot Total Knee Replacement System in 2010. Up to date, more than 550,000 medial pivot knees have been implanted globally. According to a study evaluating long-term clinical and radiographic outcomes of the medial pivot knee system published in The Knee, the results demonstrate excellent clinical outcomes for both satisfaction (95%) and survivorship (98.8%) at 17 years with patients noting a great sense of stability and comfort during regular activities.

It is expected that the academic exchange activities of Professor Blaha will help domestic orthopedic surgeons get a better understanding in the advantages of medial pivot knee. Zixin Weng, President of MicroPort® Orthopedics China, said: "We will continue to host academic activities to provide a platform for domestic and overseas knee replacement experts to exchange ideas, so as to help promote the development of China’s joint surgery industry and provide patients with better orthopedic solutions."
Dongguan Kewe Attends
17th National Thoracic and Cardiovascular Surgery Congress

From November 2 to November 4, Dongguan Kewe Medical Instrument Co., Ltd. ("Dongguan Kewe"), a wholly owned subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort"), attended the 17th National Thoracic and Cardiovascular Surgery Congress held in Hangzhou to host a satellite meeting and display its occluders and extracorporeal circulation products.

On November 4, Dongguan Kewe hosted a satellite meeting on “the Application of EverMend™ Occluder in the Treatment of Congenital Heart Disease (“CHD”)”. Director Weida Zhang of General Hospital of Guangzhou Military Command of PLA and Director Jianming Wang of Children’s Hospital of Hebei Province were invited as co-chairmen of the meeting. Director Qi Xie of Fujian Provincial Hospital, Director Jian Zuo of the First Affiliated Hospital of the Fourth Military Medical University, Director Tao Ma of General Hospital of Guangzhou Military Command of PLA, and Director Junping Yao of Children’s Hospital of Hebei Province were invited to deliver speeches respectively regarding “the Surgical and Interventional Treatment of CHD with MicroPort® Occluder,” “Evaluation of EverMend™ Occluder Treatment Efficacy and Safety”, “Transthoracic Occlusion Technique and Complication Prevention”, and “Clinical Experience in EverMend™ Occluder”. Many of them spoke highly of Dongguan Kewe’s EverMend™ Occluder for its high safety, low occurrence rate of complications, as well as excellent safety and short- and long-term efficacy.
MicroPort® Awarded
2017 Shanghai Pilot Enterprise with Outstanding Innovation

Recently, MicroPort® was awarded 2017 Shanghai Pilot Enterprise with Outstanding Innovation, the only medical device company among the ten selected enterprises. To facilitate the implantation of Shanghai government’s innovation-driven strategies to build a technological innovation center in the city and enhance its innovation ability, creativity and competitiveness, Science and Technology Commission of Shanghai Municipality and other city governmental authorities launched the “Innovative Enterprise Cultivation Program” this year to select enterprise with outstanding innovation abilities.
Investor Newsletter
Issue 11 2017

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com